Accelerated blood clearance phenomenon upon cross-administration of PEGylated nanocarriers in beagle dogs

International Journal of Nanomedicine

Volumn 10, Issue , 2015, Pages 3533-3545

  Wang, Chunling ^a   Cheng, Xiaobo ^b   Su, Yuqing ^a   Pei, Ying ^c   Song, Yanzhi ^a   Jiao, Jiao ^a   Huang, Zhenjun ^a   Ma, Yanfei ^a   Dong, Yinming ^a   Yao, Ying ^a   Fan, Jingjing ^a   Ta, Han ^a   Liu, Xinrong ^a   Xu, Hui ^a   Deng, Yihui ^a  

^a SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

^b Deli Wei Biological Technology Co Ltd   (China)

^c Shenyang Women s and Children s Hospital   (China)

Author keywords

ABC phenomenon; Cross administration; Immune response; PEGylated nanocarriers; Repeated injection

Indexed keywords

ALPHA TOCOPHEROL NICOTINATE; IMMUNOGLOBULIN M ANTIBODY; LIPOSOME; MACROGOL; NANOCARRIER; SOLID LIPID NANOPARTICLE; DRUG CARRIER; EMULSION; MACROGOL DERIVATIVE; MICELLE; NANOPARTICLE;

ANIMAL EXPERIMENT; ANTIBODY PRODUCTION; ARTICLE; BEAGLE; BLOOD LEVEL; CONTROLLED STUDY; EMULSION; IMMUNE RESPONSE; MALE; MICELLE; NONHUMAN; PARTICLE SIZE; PLASMA CLEARANCE; ANIMAL; CHEMISTRY; DOG;

CANIS FAMILIARIS;

ANIMALS; DOGS; DRUG CARRIERS; EMULSIONS; LIPOSOMES; MICELLES; NANOPARTICLES; POLYETHYLENE GLYCOLS;

EID: 84929448711     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S82481     Document Type: Article

References (51)

1. Greco F, Vicent MJ. Combination therapy: opportunities and challenges for polymer–drug conjugates as anticancer nanomedicines. Adv Drug Deliv Rev. 2009;61(13):1203–1213.
2. Broxterman HJ, Georgopapadakou NH. Anticancer therapeutics: “Addictive” targets, multi-targeted drugs, new drug combinations. Drug Resist Updat. 2005;8(4):183–197.
3. Gee J, Howell A, Gullick W, et al. Consensus statement. Endocr Relat Cancer. 2005;12(Suppl 1):S1–S7.
4. Honecker F, Kollmannsberger C, Quietzsch D, et al. Phase II study of weekly paclitaxel plus 24-h continuous infusion 5-fuorouracil, folinic acid and 3-weekly cisplatin for the treatment of patients with advanced gastric cancer. Anticancer Drugs. 2002;13(5):497–503.
5. Priotto G, Kasparian S, Mutombo W, et al. Nifurtimox-efornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III, non-inferiority trial. Lancet. 2009;374(9683):56–64.
6. Suri SS, Fenniri H, Singh B. Nanotechnology-based drug delivery systems. J Occup Med Toxicol. 2007;2(1):16.
7. Farokhzad OC, Langer R. Impact of nanotechnology on drug delivery. ACS Nano. 2009;3(1):16–20.
8. Wagner V, Dullaart A, Bock A-K, Zweck A. The emerging nanomedicine landscape. Nat Biotechnol. 2006;24(10):1211–1218.
9. Yuan F, Dellian M, Fukumura D, et al. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res. 1995;55(17):3752–3756.
10. Laginha K, Mumbengegwi D, Allen T. Liposomes targeted via two different antibodies: assay, B-cell binding and cytotoxicity. Biochim Biophys Acta. 2005;1711(1):25–32.
11. Storm G, Belliot SO, Daemen T, Lasic DD. Surface modification of nanoparticles to oppose uptake by the mononuclear phagocyte system. Adv Drug Deliv Rev. 1995;17(1):31–48.
12. Nie S. Understanding and overcoming major barriers in cancer nano-medicine. Nanomedicine. 2010;5(4):523–528.
13. Moghimi SM, Gray T. A single dose of intravenously injected poloxamine-coated long-circulating particles triggers macrophage clearance of subsequent doses in rats. Clin Sci. 1997;93(4):371–379.
14. Dams ET, Laverman P, Oyen WJ, et al. Accelerated blood clearance and altered biodistribution of repeated injections of sterically stabilized liposomes. J Pharmacol Exp Ther. 2000;292(3):1071–1079.
15. Wang C, Cheng X, Sui Y, et al. A noticeable phenomenon: thiol terminal PEG enhances the immunogenicity of PEGylated emulsions injected intravenously or subcutaneously into rats. Eur J Pharm Biopharm. 2013; 85(3):744–751.
16. Koide H, Asai T, Hatanaka K, et al. Particle size-dependent triggering of accelerated blood clearance phenomenon. Int J Pharm. 2008; 362(1–2):197–200.
17. Zhao YX, Wang L, Ya n MN, et al. Repeated injection of PEGylated solid lipid nanoparticles induces accelerated blood clearance in mice and beagles. Int J Nanomedicine. 2012;7:2891–2900.
18. Kaminskas LM, Mcleod VM, Porter H, Christopher J, Boyd BJ. Differences in colloidal structure of PEGylated nanomaterials dictate the likelihood of accelerated blood clearance. J Pharm Sci. 2011; 100(11):5069–5077.
19. Abu Lila AS, Kiwada H, Ishida T. The accelerated blood clearance (ABC) phenomenon: clinical challenge and approaches to manage. J Control Release. 2013;172(1):38–47.
20. Pozzi D, Colapicchioni V, Caracciolo G, et al. Effect of polyethyl-eneglycol (PEG) chain length on the bio–nano-interactions between PEGylated lipid nanoparticles and biological fuids: from nanostructure to uptake in cancer cells. Nanoscale. 2014;6(5):2782–2792.
21. US Department of Health and Human Services; Public Health Service; National Institutes of Health. Guide for the Care and Use of Laboratory Animals. Washington, DC: National Academy Press; 1985.
22. Zhao YX, Wang CL, Wang L, et al. A frustrating problem: accelerated blood clearance of PEGylated solid lipid nanoparticles following subcutaneous injection in rats. Eur J Pharm Biopharm. 2012;81(3): 506–513.
23. Song H, Geng H, Ruan J, et al. Development of Polysorbate 80/ Phospholipid mixed micellar formation for docetaxel and assessment of its in vivo distribution in animal models. Nanoscale Res Lett. 2011;6(1):1–12.
24. Shimada K, Miyagishima A, Sadzuka Y, et al. Determination of the thickness of the fxed aqueous layer around polyethyleneglycol-coated liposomes. J Drug Target. 1995;3(4):283–289.
25. Sadzuka Y, Nakade A, Tsuruda T, Sonobe T. Study on the characterization of mixed polyethyleneglycol modifed liposomes containing doxorubicin. J Control Release. 2003;91(3):271–280.
26. Sadzuka Y, Nakade A, Hirama R, et al. Effects of mixed poly-ethyleneglycol modification on fxed aqueous layer thickness and antitumor activity of doxorubicin containing liposome. Int J Pharm. 2002;238(1):171–180.
27. Wilson DR, Zhang N, Silvers AL, Forstner MB, Bader RA. Synthesis and evaluation of cyclosporine A-loaded polysialic acid– polycaprolactone micelles for rheumatoid arthritis. Eur J Pharm Sci. 2014;51:146–156.
28. Ichihara M, Shimizu T, Imoto A, et al. Anti-PEG IgM response against PEGylated liposomes in mice and rats. Pharmaceutics. 2010; 3(1):1–11.
29. Ishida T, Ichikawa T, Ichihara M, Sadzuka Y, Kiwada H. Effect of the physicochemical properties of initially injected liposomes on the clearance of subsequently injected PEGylated liposomes in mice. J Control Release. 2004;95(3):403–412.
30. Wang XY, Ishida T, Ichihara M, Kiwada H. Infuence of the physico-chemical properties of liposomes on the accelerated blood clearance phenomenon in rats. J Control Release. 2005;104(1):91–102.
31. Ishihara T, Takeda M, Sakamoto H, et al. Accelerated blood clearance phenomenon upon repeated injection of PEG-modifed PLA-nanoparticles. Pharm Res. 2009;26(10):2270–2279.
32. Wang X, Ishida T, Kiwada H. Anti-PEG IgM elicited by injection of lipo-somes is involved in the enhanced blood clearance of a subsequent dose of PEGylated liposomes. J Control Release. 2007;119(2):236–244.
33. Janeway CA, Travers P, Walport M, Shlomchik MJ. Immunobiology. New York, NY: Garland Science; 2001:910.
34. Szebeni J, Muggia F, Gabizon A, Barenholz Y. Activation of complement by therapeutic liposomes and other lipid excipient-based therapeutic products: prediction and prevention. Adv Drug Deliv Rev. 2011;63(12):1020–1030.
35. Owens DE III, Peppas NA. Opsonization, biodistribution, and pharmacoki-netics of polymeric nanoparticles. Int J Pharm. 2006;307(1):93–102.
36. Laverman P, Carstens MG, Boerman OC, et al. Factors affecting the accelerated blood clearance of polyethylene glycol-liposomes upon repeated injection. J Pharmacol Exp Ther. 2001;298(2):607–612.
37. Jiskoot W, van Schie RM, Carstens MG, Schellekens H. Immunologi-cal risk of injectable drug delivery systems. Pharm Res. 2009;26(6): 1303–1314.
38. Müller R, Radtke M, Wissing S. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv Drug Deliv Rev. 2002;54:S131–S155.
39. Ishida T, Wang X, Shimizu T, Nawata K, Kiwada H. PEGylated lipo-somes elicit an anti-PEG IgM response in a T cell-independent manner. J Control Release. 2007;122(3):349–355.
40. Mond JJ, Lees A, Snapper CM. T cell-independent antigens type 2. Annu Rev Immunol. 1995;13(1):655–692.
41. Mond JJ, Vos Q, Lees A, Snapper CM. T cell independent antigens. Curr Opin Immunol. 1995;7(3):349–354.
42. Joshi MD, Müller RH. Lipid nanoparticles for parenteral delivery of actives. Eur J Pharm Biopharm. 2009;71(2):161–172.
43. Liu K, Sun J, He Z-g. Development on novel nanostructured lipid carriers. J Shenyang Pharm Univ. 2008;3:017.
44. Cheng T-L, Chen B-M, Chern J-W, Wu M-F, Roffer SR. Efficient clearance of poly(ethylene glycol)-modifed immunoenzyme with anti-PEG monoclonal antibody for prodrug cancer therapy. Bioconjug Chem. 2000;11(2):258–266.
45. Cheng T-L, Wu P-Y, Wu M-F, Chern J-W, Roffer SR. Accelerated clearance of polyethylene glycol-modifed proteins by anti-polyethylene glycol IgM. Bioconjug Chem. 1999;10(3):520–528.
46. Li S-D, Huang L. Stealth nanoparticles: high density but sheddable PEG is a key for tumor targeting. J Control Release. 2010;145(3):178.
47. Needham D, Stoicheva N, Zhelev DV. Exchange of monooleoylphos-phatidylcholine as monomer and micelle with membranes containing poly(ethylene glycol)-lipid. Biophys J. 1997;73(5):2615–2629.
48. Garbuzenko O, Barenholz Y, Priev A. Effect of grafted PEG on lipo-some size and on compressibility and packing of lipid bilayer. Chem Phys Lipids. 2005;135(2):117–129.
49. Torchilin VP, Omelyanenko VG, Papisov MI, et al. Poly(ethylene glycol) on the liposome surface: on the mechanism of polymer-coated liposome longevity. Biochim Biophys Acta. 1994;1195(1):11–20.
50. Basten A, Silveira PA. B-cell tolerance: mechanisms and implications. Curr Opin Immunol. 2010;22(5):566–574.
51. Hashimoto Y, Shimizu T, Mima Y, Abu Lila AS, Ishida T, Kiwada H. Generation, characterization and in vivo biological activity of two distinct monoclonal anti-PEG IgMs. Toxicol Appl Pharmacol. 2014; 277(1):30–38.